Reports
Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Sale
The global cardiovascular drugs market is expected to grow at a CAGR of about 1.5% in the forecast period of 2021-2026.
North America dominates the global cardiovascular drugs industry, owing to the increased awareness about various heart diseases within the region. The United States represent the most important marketplace for cardiovascular drugs followed by Canada in North America. On the other hand, Asia Pacific is predicted to witness high growth rates in the coming years, thanks to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies which is further boosting the growth in the Asia Pacific region.
Additionally, increasing awareness about heart related problems is supporting within the growth of cardiovascular drugs market within the region. China, India, and Japan are expected to be the fastest growing cardiovascular drugs markets thanks to rising cases of heart diseases and extensive pipeline drugs. Increasing ageing population and rising number of lifestyle diseases are also contributing to the growth of global cardiovascular drugs industry.
Cardiovascular drugs refer to agents used for the treatment of diseases related to the cardiovascular system, which include blood clots, stroke, arteria coronaria disease, variation in vital sign, arrhythmias, high cholesterol, and coronary failure.
Cardiovascular drugs can be divided on the basis of drug type into:
On the basis of disease indication, cardiovascular drugs can be divided into:
Cardiovascular drugs can be segmented on the basis of distribution channel into:
The regional markets for global cardiovascular drugs industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Cardiovascular drugs are extremely helpful in treating various heart related dysfunction. The rising prevalence of heart stroke and cardiovascular diseases is one among the key reasons for the expansion of the cardiovascular drugs market. Cardiovascular diseases have shown stable increase in prevalence worldwide, driven by numerous modern lifestyle changes. Factors like sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors liable for the rise within the number of cardiovascular disorders among the young population. A number of the opposite crucial drivers for global cardiovascular drugs industry growth is that the increased awareness regarding cardiovascular health and therefore the corresponding increase in product launches. The rising number of diabetic patients holds immense potential to the expansion of worldwide cardiovascular drugs industry.
The report gives a detailed analysis of the following key players in the global cardiovascular drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Cardiovascular Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Cardiovascular Drugs Historical Market (2016-2020)
8.3 Global Cardiovascular Drugs Market Forecast (2021-2026)
8.4 Global Cardiovascular Drugs Market by Drug Type
8.4.1 Antihypertensive
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2016-2020)
8.4.1.3 Forecast Trend (2021-2026)
8.4.2 Antihyperlipidemic
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2016-2020)
8.4.2.3 Forecast Trend (2021-2026)
8.4.3 Anticoagulants
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2016-2020)
8.4.3.3 Forecast Trend (2021-2026)
8.4.4 Antiarrhythmics
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2016-2020)
8.4.4.3 Forecast Trend (2021-2026)
8.4.5 Others
8.5 Global Cardiovascular Drugs Market by Disease Indication
8.5.1 Hypertension
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2016-2020)
8.5.1.3 Forecast Trend (2021-2026)
8.5.2 Hyperlipidemia
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2016-2020)
8.5.2.3 Forecast Trend (2021-2026)
8.5.3 Coronary Artery Disease
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2016-2020)
8.5.3.3 Forecast Trend (2021-2026)
8.5.4 Arrhythmia
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2016-2020)
8.5.4.3 Forecast Trend (2021-2026)
8.5.5 Others
8.6 Global Cardiovascular Drugs Market by Distribution Channel
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2016-2020)
8.6.1.3 Forecast Trend (2021-2026)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2016-2020)
8.6.2.3 Forecast Trend (2021-2026)
8.6.3 Online
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2016-2020)
8.6.3.3 Forecast Trend (2021-2026)
8.6.4 Others
8.7 Global Cardiovascular Drugs Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2016-2020)
9.1.2 Forecast Trend (2021-2026)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2016-2020)
9.2.2 Forecast Trend (2021-2026)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2016-2020)
9.3.2 Forecast Trend (2021-2026)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2016-2020)
9.4.2 Forecast Trend (2021-2026)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2016-2020)
9.5.2 Forecast Trend (2021-2026)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Baxter International Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Pfizer Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Bayer AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Johnson & Johnson Services, Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Novartis AG
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Boehringer Ingelheim International GmbH
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Industry Events and Developments
Additional Customisations Available
1 Manufacturing Process
1.1 Overview
1.2 Detailed Process Flow
1.3 Operation Involved
2 Project Requirement and Cost Analysis
2.1 Land, Location and Site Development
2.2 Construction
2.3 Plant Machinery
2.4 Cost of Raw Material
2.5 Packaging
2.6 Transportation
2.7 Utilities
2.8 Manpower
2.9 Other Capital Investment
List of Figures and Tables
1. Global Cardiovascular Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global Cardiovascular Drugs Historical Market: Breakup by Drug Type (USD Billion), 2016-2020
3. Global Cardiovascular Drugs Market Forecast: Breakup by Drug Type (USD Billion), 2021-2026
4. Global Cardiovascular Drugs Historical Market: Breakup by Disease Indication (USD Billion), 2016-2020
5. Global Cardiovascular Drugs Market Forecast: Breakup by Disease Indication (USD Billion), 2021-2026
6. Global Cardiovascular Drugs Historical Market: Breakup by Distribution Channel (USD Billion), 2016-2020
7. Global Cardiovascular Drugs Market Forecast: Breakup by Distribution Channel (USD Billion), 2021-2026
8. Global Cardiovascular Drugs Historical Market: Breakup by Region (USD Billion), 2016-2020
9. Global Cardiovascular Drugs Market Forecast: Breakup by Region (USD Billion), 2021-2026
10. North America Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
11. North America Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
12. Europe Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
13. Europe Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
14. Asia Pacific Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
15. Asia Pacific Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
16. Latin America Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
17. Latin America Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
18. Middle East and Africa Cardiovascular Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
19. Middle East and Africa Cardiovascular Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
20. Global Cardiovascular Drugs Market Structure
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.